GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (OTCPK:IGXT) » Definitions » Market Cap

Intelgenx Technologies (Intelgenx Technologies) Market Cap : $28.64 Mil (As of Apr. 28, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Intelgenx Technologies Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Intelgenx Technologies's share price for the quarter that ended in Dec. 2023 was $0.13813. Intelgenx Technologies's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 174.66 Mil. Therefore, Intelgenx Technologies's market cap for the quarter that ended in Dec. 2023 was $24.13 Mil.

Intelgenx Technologies's quarterly market cap declined from Jun. 2023 ($33.19 Mil) to Sep. 2023 ($24.61 Mil) and declined from Sep. 2023 ($24.61 Mil) to Dec. 2023 ($24.13 Mil).

Intelgenx Technologies's annual market cap declined from Dec. 2021 ($55.10 Mil) to Dec. 2022 ($34.46 Mil) and declined from Dec. 2022 ($34.46 Mil) to Dec. 2023 ($24.13 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Intelgenx Technologies's Enterprise Value for Today is $41.86 Mil.


Intelgenx Technologies Market Cap Historical Data

The historical data trend for Intelgenx Technologies's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies Market Cap Chart

Intelgenx Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.15 24.51 55.10 34.46 24.13

Intelgenx Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.46 31.44 33.19 24.61 24.13

Competitive Comparison of Intelgenx Technologies's Market Cap

For the Biotechnology subindustry, Intelgenx Technologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelgenx Technologies's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intelgenx Technologies's Market Cap distribution charts can be found below:

* The bar in red indicates where Intelgenx Technologies's Market Cap falls into.



Intelgenx Technologies Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Intelgenx Technologies's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$0.13813*174.658
=$24.13

Intelgenx Technologies's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$0.13813*174.658
=$24.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intelgenx Technologies  (OTCPK:IGXT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Intelgenx Technologies Market Cap Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelgenx Technologies (Intelgenx Technologies) Business Description

Traded in Other Exchanges
Address
6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and United States.
Executives
Atai Life Sciences Ag 10 percent owner KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v. 10 percent owner 524 BROADWAY, NEW YORK NY 10013
Karen Kalayajian officer: VP, Finance&Admin - Subsidiary 4896 RUE EDOUARD-BRUNETTE, LAVAL A8 H7T 0J4
Dwight Gorham officer: CEO 15B BARKLEY ST, ARNPRIOR A6 K7S 3G8
David Kideckel officer: SVP, Corp. Dev&SA - Subsidiary 23 PEVERIL HILL SOUTH, TORONTO, ON A6 M6C 3A7
Horst G Zerbe 10 percent owner, officer: Chief Executive Officer 714 MAIN ROAD, HUDSON A8 JOP1H0
Andre Godin officer: CFO 440 DES CARMANTINES, LAVAL A8 H7X 0B6
Tommy Kenny officer: VP IP,Lgl Affairs - Subsidiary 88 CH. DES SAULES, ST-ADOLPHE D' HOWARD A8 J0T 2B0
Dana Matzen officer: VP Business+Corp. Development 4771 RUE SHERBROOKE O., WESTMOUNT A8 H3Z1G5
Ingrid Zerbe 10 percent owner, officer: Corporate Secretary 714 MAIN ROAD, HUDSON A8 J0P1H0
Rodolphe Obeid officer: Vice President, Operations 4779 RUE VILLERET, PIERREFOND A8 H9K1P6
Bernard Boudreau director 2 TURNMILL DR., HALIFAX A5 B3M4H2
John Edward Durham officer: Vice President Manufacturing 102 MAYFAIR, HUDSON A8 J0P1H0
Mark Nawacki director 118 ARLINGTON AVENUE, WESTMOUNT A8 H3Y2W4
Robert J. Bechard officer: VP Corporate Development 141 EASTON AVENUE, MONTREAL WEST A8 H4X 1L4